Join Us

We are 224,278 members in 83 forums discussing 163,476 topics.

Help with Abbreviations

Topic: Women W/ Gene Mutation Have Same/Better Survival as Women W/o

Forum: Genetic Testing —

ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, RAD51C, RAD51D, STK11, TP53, and mismatch repair genes (MLH1, MSH2, MSH6, PMS2, EPCAM)

Posted on: Sep 17, 2021 12:19PM

Moderators wrote:

Women With Breast Cancer Gene Mutation Have Same or Better Survival as Women Without Mutation
September 8, 2021

Women with a genetic mutation linked to a higher cancer risk who are diagnosed with breast cancer or ovarian cancer and receive chemotherapy treatment have the same or better survival rates as women who don't have a genetic mutation linked to higher risk. Read more...

To send a Private Message to the Mods: community.breastcancer.org/mem...
Log in to post a reply

Page 1 of 1 (5 results)

Posts 1 - 5 (5 total)

Log in to post a reply

Sep 17, 2021 12:35PM Aram wrote:

Thank you. What does below sentence mean? Does it mean women with BRCA1 are the only group who do not have better survival than those without mutation?

  • women diagnosed with ovarian cancer who had a BRCA2 mutation or a mutation other than BRCA1 or BRCA2 had better survival rates than women without a genetic mutation
Dx at 40, BRCA1 Dx 2/5/2021, IDC, Left, 1cm, Grade 3, ER-/PR-, HER2+ (IHC) Dx 2/5/2021, IDC, Left, 3cm, Grade 3, ER-/PR-, HER2+ (IHC) Chemotherapy 3/9/2021 AC + T (Taxol) Targeted Therapy 6/1/2021 Herceptin (trastuzumab) Targeted Therapy 6/2/2021 Perjeta (pertuzumab) Surgery 10/6/2021 Mastectomy: Left; Prophylactic mastectomy: Right; Reconstruction (left); Reconstruction (right)
Log in to post a reply

Sep 18, 2021 05:24AM Jelson wrote:

your cited statement is weird, might be a typo on the part of BCO because it is their summary of the study. The final quote from the study appears to apply to all mutations. Read the study and report back to Moderators.

"This is reassuring. Patients often worry that having inherited genetic risk means they are more likely to die of their cancer. Instead, they are less likely to die," said lead study author Allison Kurian, M.D., MSc, professor of medicine and epidemiology and population health at Stanford University School of Medicine, in a statement.

Dx 4/17/2009, DCIS, <1cm, Stage 0, Grade 3, 0/0 nodes, ER+/PR+
Log in to post a reply

Sep 18, 2021 12:51PM 2019whatayear wrote:

Aram yes it means that BRCA1 people w/ovarian cancer don't have *better* survival than people w/o a known mutation. They have the *same* survival as those w/o a known mutation. Which I think was not the conventional wisdom in the past. Also parps are approved for maintenance for OC cancer patients, so those w/a BRCA1 mutation get that added benefit. (not that parps are a walk in the park, but bettering the odds is worth it since OC reccurs often)

Overall in each case known germline mutation people had better or the same survival as those w/o known mutations and they believe that is because of chemo the pathogenic mutations are very sensitive to being crushed by chemo. So it's really important for mutants to get chemo in most cases.

:-) This is a really positive study IMO for people like me, thanks Mods for sharing!


5/6/2019 IDC 2cm, micromet 1/9 nodes, BRCA2+, ER+, PR+, HER- BMX 6/2019, A/C & Taxol 2019, Radiation, BSO - preventative 2/2020, Letrozole 3/1/2020, Started Lynparza for 1 year preventative on 7/18/2021
Log in to post a reply

Sep 18, 2021 09:47PM Aram wrote:

Jeldon, I believe it could have been written better.

2019whatayear, my understanding was the same as you wrote but still it is a weird way of writing it, so I wanted to make sure by asking the moderators.

Dx at 40, BRCA1 Dx 2/5/2021, IDC, Left, 1cm, Grade 3, ER-/PR-, HER2+ (IHC) Dx 2/5/2021, IDC, Left, 3cm, Grade 3, ER-/PR-, HER2+ (IHC) Chemotherapy 3/9/2021 AC + T (Taxol) Targeted Therapy 6/1/2021 Herceptin (trastuzumab) Targeted Therapy 6/2/2021 Perjeta (pertuzumab) Surgery 10/6/2021 Mastectomy: Left; Prophylactic mastectomy: Right; Reconstruction (left); Reconstruction (right)
Log in to post a reply

Sep 24, 2021 02:10PM Moderators wrote:

Hi Aram and all,

We reached out to our editorial team for some clarification. This was their response:

Thanks for your question. The bullet point means that women diagnosed with ovarian cancer with a BRCA2, or another mutation that is not BRCA1 or BRCA2, had better survival rates than women in the general population diagnosed with ovarian cancer who did not have a genetic mutation linked to a higher risk of cancer.

It does NOT mean that women with a BRCA1 mutation had worse survival than women without a mutation. It means they had the same survival as women without a mutation because, overall, the researchers found that NONE of the genetic mutations linked to a higher risk of cancer were linked to worse cancer survival.

We hope that helps!

--The Mods

To send a Private Message to the Mods: community.breastcancer.org/mem...

Page 1 of 1 (5 results)